The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances within the framework of a so-called open house procedure. See the respective lot for details.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.

The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) of the German Social Code (SGB) on various active substances/active ingredient combinations within the framework of an open house process. All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement in accordance with Section 130a (8) of the SGB V for the above-mentioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under l.1). The contracts referred to in Section I: Contracting authorities, point 1.3.) Communication named e-mail address for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contractual documents must be requested at the following e-mail address: fp_open-house@nordost.aok.de. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. Any pharmaceutical company that fulfils the eligibility requirements and documents this by signing the declarations and the discount agreement may join the discount agreement. There is no exclusivity. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The beginning of the contract can only be one month at a time. The earliest start of the contract is 01.08.2021. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2023, regardless of the date of conclusion of the contract. The offer must be submitted at the beginning of the contract on 01.08.2021 by 21.06.2021, but no contracts will be concluded by AOK Nordost before 05.07.2021. For a later commencement of the contract shall be the deadline for submission of tenders of the 5th of the previous month. (Example: Start of contract 01.09.2021; deadline for submission of the offer: 05.08.2021). If AOC Nordost grants an exclusive open procedure award for the active substance/active substance combination during the contract period, the contractual arrangements concluded within the framework of this publication shall apply. This publication does not constitute the award of a public contract within the meaning of the Coordination of Contracts Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the widest level of transparency of the contracts envisaged, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the method name of open procedure, are solely due to the use of this notice form and the publication platform. This does not imfer any further importance, in particular submission to public procurement regulations, unless they are obliged on legal grounds. Since 01.09.2016, the awarded orders will be announced exclusively on the website www.aok-gesundheitspartner.de.